Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update.

By Thomas J. Smith, Kari Bohlke, G. Lyman, K. Carson, J. Crawford, Scott J. Cross, J. Goldberg, J. Khatcheressian, N. Leighl, Cheryl L. Perkins and 4 more. Journal of Clinical Oncology, 2015

853 citations recorded by the source corpus.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/11f66209d603545b3357bd70798291b935ed6b3d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. S. Tolaney

In Oncology

1. J. Baselga
2. Michel Bolla
3. N. Mottet
4. J. Bellmunt
5. Steven Joniau
6. C. Hudis
7. Thomas Wiegel
8. S. Tolaney

Citations in the corpus

• MONARCH 1, a phase 2 study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+/HER2− metastatic breast cancer (2017, methodology): “Supportive management Hematopoetic growth factors were permitted in accordance with ASCO guidelines (25).”
• EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. (2017, methodology): “Concomitant use of granulocyte colony-stimulating factor receptor was shown to be helpful, and its use should be based on available guidelines [62].”
• EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. (2020, methodology): “Concomitant use of the granulocyte colony-stimulating factor (G-CSF) receptor was shown to be helpful, and its use should be based on available guidelines [81].”